This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Abstract Background/Aims: Conjugated linoleic acids (CLAs) affect body fat distribution, induce insulin resistance and stimulate insulin secretion. The latter effect is mediated through the free fatty acid receptor-1 (GPR40/FFAR1). This study examines whether GPR40/FFAR1 interacts with tissue specific metabolic changes induced by CLAs. Methods and Results: After chronic application of CLAs C57BL/6J wild type (WT) and GPR40/FFAR1 (Ffar1 -/-) knockout mice developed insulin resistance. Although CLAs accumulated in liver up to 46-fold genotypeindependently, hepatic triglycerides augmented only in WT mice. This triglyceride deposition was not associated with increased inflammation. In contrast, in brain of CLA fed Ffar1 -/-mice mRNA levels of TNF-α were 2-fold higher than in brain of WT mice although CLAs accumulated genotype-independently in brain up to 4-fold. Concomitantly, Ffar1 -/-mice did not respond to intracerebroventricular (i.c.v.) insulin injection with an increase in cortical activity while WT mice reacted as assessed by radiotelemetric electrocorticography (ECoG) measurements. In vitro incubation of primary murine astrocytes confirmed that CLAs stimulate
Glucose and insulin tolerance test
At day 30 of CLA treatment glucose tolerance (GTT) was assessed in overnight-fasted animals by an intraperitoneal (i.p.) administration of 2 g/kg α-D-glucose, and blood samples were taken from the tail vein to determine blood glucose concentration after 0, 15, 30, 60, and 120 min. Three days later insulin tolerance testing (ITT) was performed by injecting fed mice i.p. with 1 U/kg body weight of human insulin (Novo Nordisk, Bagsvaerd, Denmark) at 8 a.m., and blood samples were taken before and at 15, 30 , and 60 min after injection. Blood glucose concentrations were determined using a Glucometer Elite (Bayer, USA).
Measurements of electrocorticography (ECoG) by radiotelemetry
Mice were subcutaneously implanted with a telemetry electrocorticography transmitter (DSI, St Paul, MN, USA) and a cannula for intracerebroventricular (i.c.v.) injection of insulin into the cerebrospinal fluid as previously described [23] . After chronic CLA treatment the mice underwent ECoG measurements for 4 days. The monitoring was continued after i.c.v. injection of insulin (3.75 mU/5 µL) or control solution (0.9% NaCl) and recording was continuously performed during 120 min post-injection. Using fast fourier transformation for theta (4) (5) (6) (7) (8) and alpha (8) (9) (10) (11) (12) Hz) frequency bands, the power spectral density in µV 2 /Hz was calculated for ECoG measurement analysis and displayed as percentage change of control application (with 0% as baseline) to exclude inter-individual variation in baseline cortical ECoG activity. Mice which responded with a significant increase in cortical activity upon i.c.v. injection of insulin (compared to control i.c.v. application) were considered as insulin sensitive.
Cytokine measurement
Blood samples were withdrawn from the retro-orbital venous plexus of fasted mice under ketamine/ xylazine anesthesia at 8 a.m. of day 37 as terminal procedure. After centrifugation at 4°C plasma samples were stored at -20°C. Detection of cytokines (IL1-β, IL-6, and TNF-α) was done by multiplex analysis using the Bio-Plex Pro Mouse Cytokine Group I Panel (23-plex panel, Z60000DRH1, Bio-Rad, Munich, Germany). All samples were diluted 1:2 and run in duplicate. Calculation was performed with the Luminex software (LX100 IS 2.3) and results were expressed as median fluorescence intensity of 100 micro spheres of each set.
Semiquantitative PCR analysis Frozen brain, hypothalamus and liver tissue samples were homogenized in a TissueLyser (Qiagen, Hilden, Germany) and RNA was extracted with the RNeasy Tissue Kits (Qiagen). Cultured mouse primary Sartorius et 
astrocytes were lysed in QIAzol ® Lysis Reagent and RNA was prepared using QIAshredder TM and RNeasy Mini Kit (Qiagen). DNase-treated RNA samples (1 µg) were subjected to cDNA synthesis using avianmyoblastosis virus (AVMV) reverse transcriptase (Roche, Mannheim, Germany). For detection of Ffar1 gene expression, a negative control (RNA) was subjected to amplification along with every cDNA sample by omitting reverse transcriptase. RNA from Min6 cells, which were kept under standard culture conditions (Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/L glucose (Lonza, Brussels, Belgium) supplemented with 15% heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 70 µM β-mercaptoethanol in humidified 5% CO 2 , 95% air at 37°C), was used as positive control. PCR was performed using kits from Qiagen and Roche on Roche LightCycler Systems 1.5 or 480 and by using primers from Invitrogen (Darmstadt, Germany), TIB Molbiol (Berlin, Germany), and eurofins Genomics (Ebersberg, Germany). The amount of target gene mRNA was estimated relative to the house keeping gene (Rps13 or Gapdh). Sequences of all primers are listed in Table 1 .
Determination of triglyceride and CLA isomer content from tissue biopsies
Tissue samples were homogenized in PBS containing 1% Triton X-100 using a TissueLyser (Qiagen, Hilden, Germany). Triglyceride (TG) content was quantified in the homogenates using the ADVIA 1800 clinical chemistry analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). Using thin layer chromatography (TLC), the TG fraction was separated from other hepatic lipids in the homogenate. Concentrations of both CLA isomers in liver and brain tissue were measured by gas chromatography with a flame ionization detector as previously described [24] .
Primary astrocyte cultures
Primary astrocytes were isolated from pups of 2 day-old WT mice as described previously [25] and cultured in DMEM containing 4.5 g/L glucose (Lonza, Brussels, Belgium). After purification from oligodendrocytes, astrocytes were grown to confluence and cytosine-β-arabinofuranoside (Sigma-Aldrich, Taufkirchen, Germany) was then added to inhibit DNA replication. Cells were treated for 24 h with 100 µmol/L c9,t11-or t10,c12-CLA isomer (dissolved at 100 mmol/L in ethanol) ,100 µmol/L alpha-linoleic acid (dissolved at 100 mmol/L in ethanol), and with TUG-761 (10 µmol/L, dissolved in DMSO at 10 mmol/L) as indicated [26] .
Statistical analysis
Data are expressed as mean ± SEM of the indicated number of experiments and analyzed using Origin 8.1 (Northhampton, MA, USA) software. Significance for all analyses was set to P<0.05. Body weight and blood glucose concentrations (total and percental) during GTT and ITT were analyzed with a two-way ANOVA, with the factors treatment (vehicle vs. CLA) and genotype (WT vs. Ffar1 -/-mice). This automatically also tested for interaction effects between genotypes and treatment conditions (CLA-isomer concentrations and relative mRNA of TNF-α in liver, hypothalamus and brain tissue, and triglycerides in liver). Power of cortical activity after i.c.v. insulin injection was analyzed with one-way ANOVA, with the factor genotype. The Bonferroni multiple comparison procedure was used for post hoc testing. Relative mRNA of TNF-α and IL-6 within vehicle, TUG-761 or α-LA groups was calculated using one-way ANOVA, with the factor CLAisomer, followed by Bonferroni's post hoc comparisons. To compare CLA-isomers to one another within animal, one-way ANOVA was applied. 
Results

CLA ingestion reduced body weight, but induced insulin resistance in a GPR40/FFAR1 independent manner
Body weight progression was monitored during the Tonalin ® application and the impact of GPR40/FFAR1 was examined ( , CLA)). That the method of application was not responsible for this effect is suggested by the gain in body weight of mice which were fed with sunflower oil by gavage. Furthermore, food intake was not different between the groups (data not shown). These results indicate that the reduction in body weight occurred independently of GPR40/FFAR1.
Chronic CLA ingestion did not significantly affect glucose tolerance in WT mice. However, blood glucose levels of Ffar1 -/-mice increased to 30 % higher concentrations than that of WT mice, which reached significance by calculating areas under the curves (AUC) (Fig. 1B,  C) . Surprisingly, regardless of the genotype, all mice fed with CLAs developed pronounced Fig. 2A) . Notably, the concentration of the c9,t11-CLA isomer was 3-fold higher that of the t10,c12-CLA isomer in vehicle fed mice and this difference remained significant after CLA ingestion although Tonalin ® contains both isomers in equal amount. Despite the identical accumulation of CLAs, hepatic triglyceride content was significantly increased only in WT but not in Ffar1 -/-mice (Fig. 2B ). This increase of liver triglycerides was not accompanied by increased inflammation (Fig. 2C) .5 pg/mL). When expression of GPR40/ FFAR1 was examined we failed to detect receptor expression in mouse liver while significant (P<0.001) amounts of GPR40/FFAR1 mRNA were detectable in an insulin-secreting mouse cell line used as positive control (Fig. 3A, B) . These observations suggest that GPR40/FFAR1 activity indirectly supports liver triglyceride accumulation.
GPR40/FFAR1 deficiency increased neuronal inflammation and induced brain insulin resistance
Inflammation and insulin resistance of the brain impact on peripheral glucose homeostasis and regulate body energy repartition. Therefore, the accumulation of CLAs in brain and their effects on the inflammation marker TNF-α and brain insulin sensitivity was examined in WT and Ffar1 -/-mice. In vehicle fed WT and Ffar1 -/-mice the CLA content of whole brain homogenates was identical and the concentration of the c9,t11-CLA isomer was 3-fold higher than that of the t10,c12-CLA isomer (Fig. 4 A, white and black columns) . Sartorius 
Irrespective of the genotype, after chronic Tonalin ® ingestion, the difference in concentration between the isomers persisted with a 4-fold increase of the c9,t11-CLA isomer up to 14 µg/g brain tissue, and a 3-fold increase of the t10,c12-CLA up to 3 µg/g brain tissue (Fig.  4 A) . Although the accumulation of CLA isomers was identical between the genotypes, the mRNA levels of the inflammation marker TNF-α were significantly higher and coincided with reduced insulin sensitivity of the brain in chronically CLA-treated Ffar1 -/-mice compared to WT mice and vehicle mice fed regular chow diet (Fig. 4B-D) . Expression analysis of Ffar1 mRNA revealed no detectable levels in mouse brain (data not shown) indicating that GPR40/ FFAR1 indirectly, through organ crosstalk, protected the brain from inflammation and insulin resistance induced by CLAs.
That CLA isomers induce inflammation is further suggested by the increase in mRNA of TNF-α and IL-6 in astrocyte cultures of WT mice ( Fig. 5A and B) . This effect is not mediated by GPR40/FFAR1 as it persisted in the presence of the GPR40/FFAR1 inhibitor TUG-761 ( Fig. 5A and B) . That the conjugated double bond system accounts for the inflammatory response is suggested by exposing primary murine astrocytes to 100 µM alpha-linoleic acid (α-LA) (as well as co-treatment of α-LA with CLA-isomers). No significant increase of TNF-α and IL-6 gene expression was detected with α-LA alone, whereas additional treatment with both CLA-isomers increased these parameters (Fig. 5A and B) . In addition, Ffar1 mRNA was also not detectable in primary murine astrocytes (Fig. 3C) .
These observations suggest that oral ingestion of Tonalin ® lead to an accumulation of CLAs in brain cells, where they induce inflammation and insulin resistance. GPR40/FFAR1 counteracts the two latter effects. 
Discussion
Apart from CLA-induced stimulation of insulin secretion through the direct activation of beta-cell specific GPR40/FFAR1 this study now gives evidence that GPR40/FFAR1 activation protects from adverse effects of CLA accumulation in brain. By the use of GPR40/FFAR1 knockout mice it became apparent that CLAs are able to induce local inflammation and concomitantly insulin resistance in the brain. That CLAs directly induce local inflammation in brain was further corroborated in vitro using isolated primary mouse astrocytes.
The protective effect of GPR40/FFAR1 on CLA-induced changes in the brain is most probably indirectly exerted through organ crosstalk as we were unable to detect mRNA levels of Ffar1 in mouse brain by qRT-PCR. In a recent study, however, using in situ hybridization GPR40/FFAR1-specific signals were found in restricted mouse brain areas [12] . Recently, we described a direct protective effect of GPR40/FFAR1 agonists on betacell death [26] . An indirect effect of GPR40/FFAR1 on neuronal inflammation and insulin resistance induced by CLA accumulation may come from CLA-induced GPR40/FFAR1-dependent stimulation of insulin and GLP-1 secretion [7, 10] . Indeed, GLP-1 has been found to be neuroprotective and could therefore limit local inflammation induced by CLAs in WT mice [27] . Furthermore, increasing evidence suggests that insulin exerts direct effects on Sartorius et 
brain function, and this effect may have an impact on whole body glucose homeostasis [28, 29] . Possible direct effects of CLAs mediated by brain GPR40/FFAR1 receptors need to be explored in humans and macaques where the receptor is abundantly expressed [13] [14] [15] . Although CLAs locally induced low-grade inflammation in brain, plasma concentrations of IL-6, TNF-α and IL1-β remained unchanged. In accordance, in a study of Parra et al. no impaired inflammatory status could be detected in mice treated with moderate doses of CLAs [30] . However, CLAs induced inflammation in adipose tissue and this has been associated with insulin resistance and fat cell apoptosis [31, 32] . Liver inflammation remained undetectable. This implies that the tissue-specific changes of inflammation marker remain local and this could explain the partly opposing effects of CLAs observed in distinct tissues.
The finding that both CLA-isomers increased TNF-α and IL-6 mRNA in primary astrocyte cultures indicate that astrocytes may contribute to neuronal inflammation as Ffar1 mRNA was not detectable, and the antagonist TUG-761 did not inhibit CLA-induced cytokine production. However, this effect is independent of GPR40/FFAR1 as corroborated with the antagonist TUG-761 [26] . Indeed, astrocytes have been found to contribute to the local immune response within the brain through the production of both pro-and anti-inflammatory cytokines and chemokines [33] . Astrocytes, upon producing IL-6, affect neurogenesis [34, 35] . Recently, we published that mice deficient of TLR2 and 4 express lower levels of IL-6 mRNA in astrocytes and this impacts on cortical activity and physical behavior [36] . Furthermore, astrocytes have a role in brain fatty acid metabolism [37, 38] . They produce docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6) and are involved in the metabolism of highly unsaturated n-3 and n-6 fatty acids. In isolated astrocytes from rat's cerebellum Fa et al. investigated the ability to take up the two CLA isomers and to degrade them into shorter fatty acids [17] . An efficient peroxisomal β-oxidation of predominantly the t10,c12-CLA isomer and an inhibition in the elongation step of this CLA isomer was found, demonstrating the ability of the brain to incorporate CLAs and to metabolize them in situ. The more efficient peroxismal β-oxidation of predominantly the t10,c12-CLA isomer might further account for the 3-fold higher concentration of the c9,t11-CLA isomer than that of the t10,c12-CLA isomer, which we found both in whole brain homogenates and in liver tissue. Although a direct application of CLAs into the cerebrospinal fluid decreased appetiteregulating neuropeptides [19] , CLA incorporation into brain lipids by in vivo feeding does not correlate with changes in appetite-regulating neuropeptides and reductions in food intake [39] . We observed no change in food intake (data not shown) and in mRNA levels of NPY during CLA feeding (data not shown). These findings make it unlikely that the reduction in body weight is a consequence of altered neuronal regulation of food intake. Indeed, a reduction of body weight after CLA ingestion was not observed in all studies [40, 41] . It is noteworthy that Tonalin ® is used as nutrient additive to build up muscle mass in humans, and exercise is one of the regulatory parameters to prevent hepatic steatosis and adiposity. The consequence of additional exercise on CLA-induced hepatic steatosis was not part of our experimental design, but further studies should include endurance exercise.
That CLAs exert effects in brain and affect neuronal function is further supported by the fact that lately, a negative correlation was found between CLA and Alzheimer's disease [42] . In a human neuroblastoma cell line, CLA-isomers decreased tau phosphorylation and showed neuroprotective effects against β-amyloid peptides through a specific inhibition of the calcium-dependent cysteine protease µ-calpain. Emerging evidence has indicated that altered neurogenesis in the adult hippocampus represents an early critical event in the context of Alzheimer's disease [43] .
In contrast to the brain, CLA accumulation in liver of WT mice was not accompanied by an increase in local inflammation markers, which is different to HFD-driven fatty liver with increased hepatic inflammation. GPR40/FFAR1 deficiency protected against CLA-induced accumulation of hepatic triglycerides. The reduction in hepatic fat deposition in Ffar1 -/-mice does not seem to be mediated by a direct activation of GPR40/FFAR1 as receptor expression was not detectable in liver tissue. The most plausible link between a reduction in liver fat storage and GPR40/FFAR1 deficiency might be the lack of CLA-induced augmentation of insulin secretion. Indeed, CLAs directly stimulate insulin secretion through GPR40/FFAR1 [7] . As a consequence, insulin resistance is most efficiently compensated in the presence of GPR40/FFAR1. Thus, although CLA-induced stimulation of GPR40/FFAR1 is beneficial for the maintenance of glucose tolerance, insulin hypersecretion mediated by GPR40/FFAR1 may contribute to the development of fatty liver. That insulin contributes to CLA-induced fatty liver has been proposed previously [44] . Of note, a previous study using the same mouse model described a reduced accumulation of triglycerides in Ffar1 -/-mice fed a HFD [20] . In our study, young mice were fed with chow diet and approximately ingested 50 kJ/ day. Supplementation with CLAs increased the daily ingested energy by 1-2%. Therefore, an exaggerated energy intake does not explain the development of insulin resistance and the increase in liver triglycerides after Tonalin ® treatment. CLAs probably increase fat deposit in liver as they reduce energy uptake into adipocytes [45] . Indeed, the animals were fed with chow diet and food intake between vehicle and CLA-treated animals was not different.
In summary, chronic ingestion of CLAs induces insulin resistance and local inflammation in the brain and this associate with local insulin resistance of the brain in Ffar1 -/-mice. The in vivo experiments with Ffar1 -/-mice deciphered that GPR40/FFAR1 protects against CLAinduced brain inflammation and insulin resistance, although the expression of functional receptors accentuated liver steatosis. Taking into account our previous finding that CLAs stimulate insulin secretion through GPR40/FFAR1 and the present study which gives evidence that CLAs may induce brain inflammation and insulin resistance of the brain, CLAs should be reevaluated and not considered as safe food additives but as pharmacological drugs.
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